Melodiol Global Health (ASX:ME1DE) EBIT : A$-25.83 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Melodiol Global Health EBIT?

Melodiol Global Health's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was A$-2.66 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-25.83 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Melodiol Global Health's annualized ROC % for the quarter that ended in Dec. 2023 was -24.85%. Melodiol Global Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -53.55%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Melodiol Global Health's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -214.77%.

Melodiol Global Health EBIT Historical Data

The historical data trend for Melodiol Global Health's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Melodiol Global Health EBIT Chart

Melodiol Global Health Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-13.25

-21.51

-28.33

-32.09

-25.83

Melodiol Global Health Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT	Get a 7-Day Free Trial										-10.03	-7.08	-25.01	-23.17	-2.66

Competitive Comparison of Melodiol Global Health's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Melodiol Global Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Melodiol Global Health's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Melodiol Global Health's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Melodiol Global Health's EV-to-EBIT falls into.

Melodiol Global Health EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-25.83 Mil.

Melodiol Global Health (ASX:ME1DE) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Melodiol Global Health's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-7.016 * ( 1 - 0.1% )	/	( (32.85	+	23.568)	/ 2 )
=	-7.008984	/	28.209
=	-24.85 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	32.805	-	12.363	-	( 1.078	-	max(0, 23.49	-	11.082	+	1.078	))
=	32.85

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	19.044	-	12.974	-	( 0.692	-	max(0, 23.018	-	5.52	+	0.692	))
=	23.568

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Melodiol Global Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-5.32	/	( ( (10.214 + max(-2.776, 0))	+	(9.655 + max(-9.21, 0)) )	/	2 )
=	-5.32	/	( ( 10.214	+	9.655 )	/	2 )
=	-5.32	/	9.9345
=	-53.55 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(4.741	+	2.245	+	3.018)	-	(12.363	+	0	+	0.417)
=	-2.776

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2.394	+	1.461	+	0.391)	-	(12.974	+	0	+	0.482)
=	-9.21

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Melodiol Global Health's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-25.832	/	12.028
	=	-214.77 %

Melodiol Global Health EBIT Related Terms

Thank you for viewing the detailed overview of Melodiol Global Health's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Melodiol Global Health (ASX:ME1DE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Melodiol Global Health Ltd (ASX:ME1DE) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

COPHF:USA

Address

145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009

Website

https://www.cresopharma.com

Melodiol Global Health Ltd is engaged in developing, registering, and commercialization of pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health. Its brands include Mernova: A licensed producer of cannabis products in Canada for sale under the Ritual brand banner. Sierra Sage Herbs: US-based developer of plant-based, beauty, and personal care brands Green Goo, Southern Butter, and Good Goo. impACTIVE: CBD topical products for athletes. Halucenex: Clinical stage psychedelics research and development operation. Creso Pharma Switzerland: CBD-related research, development, and commercialization.

Melodiol Global Health (ASX:ME1DE) Headlines

No Headlines